Aslıhan Gürün Kaya, Aydın Çiledağ, Serhat Erol, Miraç Öz, Deniz Doğan Mülazımoğlu, Özlem Işık, Hilal Özakıncı, Fatma Çiftçi, Elif Şen, Koray Ceyhan, Akın Kaya, Demet Karnak, Gökhan Çelik, Savaş İsmail
{"title":"评估EBUS-TBNA细胞学样本中肺癌生物标志物谱以决定靶向治疗。","authors":"Aslıhan Gürün Kaya, Aydın Çiledağ, Serhat Erol, Miraç Öz, Deniz Doğan Mülazımoğlu, Özlem Işık, Hilal Özakıncı, Fatma Çiftçi, Elif Şen, Koray Ceyhan, Akın Kaya, Demet Karnak, Gökhan Çelik, Savaş İsmail","doi":"10.1177/00369330221078995","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Guidelines recommend performing biomarker tests for epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), BRAF and ROS proto-oncogene-1(ROS1) genes and protein expression of programmed death ligand-1(PD-L1) in patients with non-small lung cell carcinoma (NSCLC). Studies reported that endobronchial ultrasound-transbronchial needle aspiration (EBUS-TBNA) can provide sufficient material for cancer biomarker analyses, but there are still concerns about the subject.</p><p><strong>Aim: </strong>The purpose of the study was to assess the adequacy of EBUS-TBNA for testing lung cancer biomarkers.</p><p><strong>Methods: </strong>We retrospectively reviewed patients with NSCLC whose EBUS-TBNA was analysed for EGFR, ALK, ROS-1, BRAF and PD-L1 expression between December 2011 and December 2020.</p><p><strong>Results: </strong>A total of 394 patients were enrolled in the study. EGFR mutation and ALK fusion were the most common studied biomarkers. EBUS-TBNA adequacy rate for biomarker tests was found 99.0% for EGFR, 99.1 for ALK, 97.2% for ROS1, 100% for BRAF and 99.3% for PD-L1 testing. Multivariate analysis revealed the histological type, history of treatment for NSCL, size, or 18-fluorodeoxyglucose uptake of sampled lesion did not show any association with TBNA adequacy for biomarker testing.</p><p><strong>Conclusion: </strong>EBUS-TBNA can provide adequate material for biomarker testing for EGFR, ALK, ROS-1, BRAF and PD-L1 expression.</p>","PeriodicalId":21683,"journal":{"name":"Scottish Medical Journal","volume":"67 1","pages":"18-27"},"PeriodicalIF":1.4000,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":"{\"title\":\"Evaluation of lung cancer biomarkers profile for the decision of targeted therapy in EBUS-TBNA cytological samples.\",\"authors\":\"Aslıhan Gürün Kaya, Aydın Çiledağ, Serhat Erol, Miraç Öz, Deniz Doğan Mülazımoğlu, Özlem Işık, Hilal Özakıncı, Fatma Çiftçi, Elif Şen, Koray Ceyhan, Akın Kaya, Demet Karnak, Gökhan Çelik, Savaş İsmail\",\"doi\":\"10.1177/00369330221078995\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Guidelines recommend performing biomarker tests for epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), BRAF and ROS proto-oncogene-1(ROS1) genes and protein expression of programmed death ligand-1(PD-L1) in patients with non-small lung cell carcinoma (NSCLC). Studies reported that endobronchial ultrasound-transbronchial needle aspiration (EBUS-TBNA) can provide sufficient material for cancer biomarker analyses, but there are still concerns about the subject.</p><p><strong>Aim: </strong>The purpose of the study was to assess the adequacy of EBUS-TBNA for testing lung cancer biomarkers.</p><p><strong>Methods: </strong>We retrospectively reviewed patients with NSCLC whose EBUS-TBNA was analysed for EGFR, ALK, ROS-1, BRAF and PD-L1 expression between December 2011 and December 2020.</p><p><strong>Results: </strong>A total of 394 patients were enrolled in the study. EGFR mutation and ALK fusion were the most common studied biomarkers. EBUS-TBNA adequacy rate for biomarker tests was found 99.0% for EGFR, 99.1 for ALK, 97.2% for ROS1, 100% for BRAF and 99.3% for PD-L1 testing. Multivariate analysis revealed the histological type, history of treatment for NSCL, size, or 18-fluorodeoxyglucose uptake of sampled lesion did not show any association with TBNA adequacy for biomarker testing.</p><p><strong>Conclusion: </strong>EBUS-TBNA can provide adequate material for biomarker testing for EGFR, ALK, ROS-1, BRAF and PD-L1 expression.</p>\",\"PeriodicalId\":21683,\"journal\":{\"name\":\"Scottish Medical Journal\",\"volume\":\"67 1\",\"pages\":\"18-27\"},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2022-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Scottish Medical Journal\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/00369330221078995\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/2/11 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Scottish Medical Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/00369330221078995","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/2/11 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
Evaluation of lung cancer biomarkers profile for the decision of targeted therapy in EBUS-TBNA cytological samples.
Background: Guidelines recommend performing biomarker tests for epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), BRAF and ROS proto-oncogene-1(ROS1) genes and protein expression of programmed death ligand-1(PD-L1) in patients with non-small lung cell carcinoma (NSCLC). Studies reported that endobronchial ultrasound-transbronchial needle aspiration (EBUS-TBNA) can provide sufficient material for cancer biomarker analyses, but there are still concerns about the subject.
Aim: The purpose of the study was to assess the adequacy of EBUS-TBNA for testing lung cancer biomarkers.
Methods: We retrospectively reviewed patients with NSCLC whose EBUS-TBNA was analysed for EGFR, ALK, ROS-1, BRAF and PD-L1 expression between December 2011 and December 2020.
Results: A total of 394 patients were enrolled in the study. EGFR mutation and ALK fusion were the most common studied biomarkers. EBUS-TBNA adequacy rate for biomarker tests was found 99.0% for EGFR, 99.1 for ALK, 97.2% for ROS1, 100% for BRAF and 99.3% for PD-L1 testing. Multivariate analysis revealed the histological type, history of treatment for NSCL, size, or 18-fluorodeoxyglucose uptake of sampled lesion did not show any association with TBNA adequacy for biomarker testing.
Conclusion: EBUS-TBNA can provide adequate material for biomarker testing for EGFR, ALK, ROS-1, BRAF and PD-L1 expression.
期刊介绍：
A unique international information source for the latest news and issues concerning the Scottish medical community. Contributions are drawn from Scotland and its medical institutions, through an array of international authors. In addition to original papers, Scottish Medical Journal publishes commissioned educational review articles, case reports, historical articles, and sponsoring society abstracts.This journal is a member of the Committee on Publications Ethics (COPE).
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
